Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP)

i

Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP)

Current Public Domain

05/23/2018
By Centers for Disease Control and Prevention (U.S.).

File Language:

English

Details

Corporate Authors:

Centers for Disease Control and Prevention (U.S.).
Description:

Guidance to providers regarding the use of Dolutegravir. A preliminary unscheduled analysis of data from an ongoing NIH-funded observational study in Botswana suggests that an increased risk of neural tube defects was associated with exposure to antiretroviral (ARV) regimens that include dolutegravir (DTG) at conception.
Subjects:

HIV Pregnant Women
Document Type:

Journal Article
Place as Subject:

United States
Collection(s):

Guidelines and Recommendations
Main Document Checksum:

urn:sha-512:27f7f367b98be358a4a8ca66bb6930d889f028c967810a282bc6ca79d022f00a2ae9ffc929d6946466fc6d43b2c60ce202b495d9c14012c66097ebb7e5efd5aa
Download URL:

https://stacks.cdc.gov/view/cdc/80420/cdc_80420_DS1.pdf
File Type:

[PDF - 103.71 KB ]

File Language:

English

ON THIS PAGE

Details

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.